Restoring Function & Enhancing Lives

Histogen is a clinical-stage therapeutics company focused on developing potential first-in-class restorative therapeutics that ignite the body’s natural process to repair and maintain healthy biological function. Histogen’s innovative technology platform utilizes cell conditioned media and extracellular matrix materials produced by hypoxia-induced multipotent cells. Histogen’s proprietary, reproducible manufacturing process provides targeted solutions across a broad range of therapeutic indications including hair growth, dermal rejuvenation, joint cartilage regeneration and spinal disk repair.

clinical programs

Histogen is advancing three clinical programs in therapeutic indications with large commercial market opportunities:

HAIR GROWTH

Hair Growth

A minimally-invasive treatment that is intended to grow new hair, not simply preserve existing hair.

SKIN CARE

Dermal Fillers

Human-derived collagen and extracellular matrix dermal fillers delivering potentially longer-lasting effects with fewer side effects for the treatment of facial folds and wrinkles.

MATRIX REGENERATION

Joint Cartilage Repair

Histogen’s extracellular matrix for articular cartilage defects regenerates hyaline cartilage for the treatment of knee osteoarthritis with a novel malleable scaffold produced by the body’s own stem cells.

Latest News

August 31, 2021
Histogen to Present at the H.C. Wainwright 23rd Annual Global Investment Conference

SAN DIEGO, Aug. 31, 2021 (GLOBE NEWSWIRE) -- Histogen Inc. (NASDAQ: HSTO), a clinical-stage therapeutics company focused on developing potential first-in-class restorative therapeutics that ignite the body’s natural process to repair and maintain healthy biological function, today announced that

August 16, 2021
Histogen and Amerimmune Announce Additional Findings from its Phase 1 Study of Emricasan in Mild Symptomatic COVID-19 Patients

Immunological Data Highlights How Caspase Inhibition May Prevent COVID-19 Disease Progression Emricasan Found to Have Statistically Significant Improvements in Clinically Relevant Hematological and Immune Markers Which May Lead to Potential Clinical Benefits in COVID-19 Patients SAN DIEGO, Aug.

August 11, 2021
Histogen Reports Second Quarter 2021 Earnings and Provides Business Update

Company to Focus its Regenerative Medicine Technology Platform on Developing Orthopedic Product Candidates Initiated Phase 1/2 Study of HST 003 for Cartilage Regeneration in the Knee HST 004 Selected as Product Candidate for Spinal Disc Repair with IND Enabling Activities Underway Positive Top-Line